ACADIA PHARMACEUTICALS INC (ACAD) Most Active Options
The 21 most actively traded ACADIA PHARMACEUTICALS INC (ACAD) option contracts at the latest daily snapshot, ranked by volume. Each row shows the contract's price, implied volatility, delta, open interest, and how today's volume compares with its own 30-day average — click a contract to analyze it in the OptiView platform.
Data as of Aug 24, 2026, 3:55 PM ET · OPRA data 15 minutes delayed · For information only — not investment advice.
Most Active ACAD Contracts
| Contract | Expiration | DTE | Last | IV | IV rank (30d) | Delta | Open interest | Volume | vs 30d avg |
|---|---|---|---|---|---|---|---|---|---|
| ACAD $40 call | Sep 18, 2026 | 25d | $0.40 | — | 20 | — | 1,004 | 514 | 8.2× avg |
| ACAD $34 call | Sep 18, 2026 | 25d | $0.55 | — | 37 | — | 15 | 271 | 8.2× avg |
| ACAD $31 call | Sep 18, 2026 | 25d | $1.25 | — | 93 | — | 324 | 164 | 2.0× avg |
| ACAD $30 call | Sep 18, 2026 | 25d | $1.55 | — | 90 | — | 1,555 | 126 | 1.6× avg |
| ACAD $29 call | Sep 18, 2026 | 25d | $2.15 | — | 65 | — | 1,876 | 81 | 2.3× avg |
| ACAD $29 put | Sep 18, 2026 | 25d | $1.75 | — | 56 | — | 1,228 | 72 | 1.9× avg |
| ACAD $35 call | Oct 16, 2026 | 53d | $2.35 | — | 61 | — | 26 | 22 | 0.7× avg |
| ACAD $30 call | Oct 16, 2026 | 53d | $3.90 | 84.2% | 67 | 0.57 | 1,175 | 20 | 0.3× avg |
| ACAD $26 put | Oct 16, 2026 | 53d | $2.14 | — | 95 | — | 3 | 16 | 11.8× avg |
| ACAD $35 call | Sep 18, 2026 | 25d | $0.60 | — | 32 | — | 39 | 13 | 0.4× avg |
| ACAD $20 put | Jan 15, 2027 | 144d | $0.80 | — | 16 | — | 19 | 10 | 3.6× avg |
| ACAD $32 put | Sep 18, 2026 | 25d | $3.70 | — | — | — | 0 | 6 | — |
| ACAD $30 put | Sep 18, 2026 | 25d | $1.29 | — | 24 | — | 1 | 6 | 0.2× avg |
| ACAD $35 call | Dec 18, 2026 | 116d | $3.14 | 72.3% | 86 | 0.45 | 72 | 3 | 1.1× avg |
| ACAD $28 call | Sep 18, 2026 | 25d | $2.85 | — | 87 | — | 227 | 2 | 0.3× avg |
| ACAD $27 call | Dec 18, 2026 | 116d | $6.52 | — | 87 | — | 48 | 1 | 0.3× avg |
| ACAD $29 call | Dec 18, 2026 | 116d | $5.00 | 0.0% | 0 | 1.00 | 99 | 1 | 0.3× avg |
| ACAD $33 call | Oct 16, 2026 | 53d | $1.50 | — | 73 | — | 49 | 1 | 0.0× avg |
| ACAD $25 put | Dec 18, 2026 | 116d | $2.30 | — | 42 | — | 1 | 1 | 8.4× avg |
| ACAD $32 call | Sep 18, 2026 | 25d | $1.30 | — | 30 | — | 2 | 1 | 0.0× avg |
| ACAD $25 put | Jan 15, 2027 | 144d | $2.55 | 0.0% | 0 | 1.00 | 7 | 1 | 0.2× avg |
Ranked by volume at the latest daily snapshot. "vs 30d avg" compares today's volume with the contract's own 30-day average.
The most active ACAD contract today is the $40 call expiring in 25 days, with 514 contracts traded. Calls dominate the most-active list (14 of the top 21), showing where trading interest concentrates. One of these contracts is running well ahead of the usual daily volume.
Explore the payoff profile of option on ACAD for free
Build multi-leg ACAD strategies, visualize payoffs, and scan the full US options universe with OptiView.
ACAD Options FAQ
Which ACAD option contract is most active today?
The most traded ACAD contract is the $40 call expiring Sep 18, 2026, with 514 contracts traded as of Aug 24, 2026.
How does OptiView rank the most active ACAD options?
The table lists the 21 ACAD contracts with the highest volume at the latest daily snapshot, alongside price, implied volatility, delta, open interest, and each contract's volume versus its own 30-day average.
Methodology. IV rank compares the current 30-day at-the-money implied volatility with its highest and lowest values over the past 52 weeks. Max pain is the strike that minimizes the total payout to option holders at expiration. The call and put walls are the strikes carrying the largest call and put open interest across all expirations. Net gamma exposure (GEX) is measured from the dealer perspective. All statistics are derived from delayed OPRA options data.
Options trading involves significant risk, and losses can exceed your initial investment. Always consult a licensed financial professional before making investment decisions. OptiView does not provide financial advice; all figures on this page are descriptive statistics, not recommendations.